FDA Approves Single Pill HIV Treatment genre: Gaylingual & Little Red Ribbon-Hood
For the first time in the history of HIV, the Food and Drug Administration has approved a single pill therapy for the treatment of the disease that is expected to be made make available for use in the U.S. within approximately a week.
The pill, a combination of three different drugs is called Atripla and it is the result of a collaboration of two pharmaceutical companies, Gillead Inc. and Bristol-Meyers Squibb Company. The three drugs were previously the FDA's recommended first line treatment regimen. Read the full article here.
Atripla, which contains Bristol-Myers Squibb Co.'s drug Sustiva and Gilead Inc.'s medicines Viread and Emtriva, is the latest step in making it easier for AIDS patients to keep the human immunodeficiency virus or HIV in check -- a process that once included dozens of daily pills.
Atripla will cost $1,150.88 for a 30-day supply and will be available within seven business days, the drugmakers said.
In June, the FDA approved another three-in-one AIDS pill for use in poor countries under a global relief plan. That product contains generic versions of older HIV drugs, and the combination is not sold in the United States.
Daniel DiRito | July 12, 2006 | 7:24 PM
Comments
Trackback Pings
© Copyright 2024
Post a comment